These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34503415)

  • 1. Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.
    Monteiro A; Yu KOA; Hicar MD
    Curr HIV Res; 2021; 19(6):465-475. PubMed ID: 34503415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
    Steffen I; Pöhlmann S
    Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.
    Smith M; Hoffman J; Sojar H; Aalinkeel R; Hsiao CB; Hicar MD
    Curr HIV Res; 2018; 16(6):404-415. PubMed ID: 30836922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins.
    Debnath AK
    Curr Opin Investig Drugs; 2006 Feb; 7(2):118-27. PubMed ID: 16499281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions.
    Veiga S; Yuan Y; Li X; Santos NC; Liu G; Castanho MA
    Biochim Biophys Acta; 2006 Jan; 1760(1):55-61. PubMed ID: 16290276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV-1 by fusion inhibitors.
    Eggink D; Berkhout B; Sanders RW
    Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
    Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
    AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide, the first fusion inhibitor to treat HIV infection.
    Poveda E; Briz V; Soriano V
    AIDS Rev; 2005; 7(3):139-47. PubMed ID: 16302461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.